SCHEMBL3973138

SCHEMBL3973138

Cc1ccc2nc(-c3ccc(Br)cc3)nc(NCCC3CCCN3C)c2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CAMK2D Q13557 1/20 0.49
ACP1 P24666 3/20 0.47
KDM1A O60341 2/20 0.46
USP2 O75604 1/20 0.45
ALOX15 P16050 1/20 0.45
HSD17B10 Q99714 1/20 0.45
HRH2 P25021 1/20 0.43
HRH1 P35367 1/20 0.43
HRH3 Q9Y5N1 1/20 0.43
RAD52 P43351 3/20 0.41
POLB P06746 2/20 0.41
SMARCA2 P51531 1/20 0.41
PDE5A O76074 2/20 0.40
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 1/20 0.40
MAPT P10636 1/20 0.40
HTT P42858 1/20 0.40
KMT2A Q03164 1/20 0.40
TERT O14746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3975341 0.89 CAMK2D (0.61) CAMK2DACP1HRH2HRH1HRH3
SCHEMBL3975061 0.85 TLR9 (0.52) CAMK2DACP1KDM4EALDH1A1MAPT
SCHEMBL3971152 0.82 KDM4E (0.45) HSD17B10POLBPDE5AKDM4EALDH1A1
SCHEMBL3975321 0.79 SLC2A1 (0.49) ACP1USP2ALOX15HSD17B10RAD52
SCHEMBL3979247 0.78 ALDH1A1 (0.54) ACP1USP2ALOX15HSD17B10RAD52
SCHEMBL3974310 0.77 GBA1 (0.51) RAD52POLBSMARCA2PDE5AMEN1
SCHEMBL3975234 0.77 ACP1 (0.60) ACP1USP2ALOX15HSD17B10RAD52
SCHEMBL3976459 0.77 MAPT (0.67) ACP1USP2ALOX15HSD17B10POLB
SCHEMBL3975873 0.76 ADORA1 (0.55) ACP1USP2ALOX15HSD17B10RAD52
SCHEMBL3973275 0.76 RAD52 (0.69) ACP1RAD52POLBSMARCA2PDE5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7547702-B2 4-amino-quinazolines ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2009-06-16 US disclosed
US-20060019974-A1 Glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents ORTHO-MCNEIL PHARMACEUTICALS, INC. 2006-01-26 US disclosed
WO-2004030672-A1 USE OF 4 AMINO-QUINAZOLINES AS ANTI CANCER AGENTS MERCK PATENT GMBH (DE) 2004-04-15 WO disclosed
EP-1318984-A1 4-AMINO-QUINAZOLINES MERCK PATENT GmbH (DE) 2003-06-18 EP disclosed
WO-2002024667-A1 4-AMINO-QUINAZOLINES MERCK PATENT GMBH (DE) 2002-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060019974-A1 Glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents SERPINA3, APOL1, MGAT3 CAMK2D 2629/4885ACP1 4097/4885KDM1A 4644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.